Giuffrida et al. reported an increased efficacy of A2aR-KO CAR T cells compared to pharmacological A2aR blockade or A2aR-KD, yet raised the concern on decreased persistence of A2aR-KO CARs in the tumor microenvironment [102]. Here, ADORA2A is linked to neoplasm.